The drug gentamicin increased dystrophin levels in boys with DMD due to a nonsense mutation, but didn't improve strength at the doses used

posted on April 14, 2010 - 3:34am
Results of the MDA-supported trial of gentamicin in Duchenne muscular dystrophy (DMD) were presented Wednesday, April 14, at the annual meeting of the American Academy of Neurology (AAN), held in Toronto. Levels of the needed dystrophin protein increased in six out of 12 participants who received the drug for six months. No functional improvements were seen.

New content is being added every day. Please check back again.